Importantly, reference omalizumab and/or free IgE concentrations have been demonstrated to correlate with clinical outcomes in populations of patients with asthma or urticaria,23, 24, 25 underlining the importance of assessing these measures when evaluating candidate biosimilars of reference omalizumab. Here, IGHE is linked to urticaria.